No Data
Autolus Therapeutics Announces Publication of Data From the FELIX Study of Obe-cel in R/r Adult B-ALL Patients in The New England Journal of Medicine
Is Autolus Therapeutics (NASDAQ:AUTL) Using Too Much Debt?
European Equities Traded in the US as American Depositary Decline in Tuesday Trading
Goldman Sachs Upgrades Autolus Therapeutics(AUTL.US) to Buy Rating, Raises Target Price to $7.6
Autolus Therapeutics Analyst Ratings
Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
